Insider Transaction Report for Mao Li

This filing details a transaction by Mao Li, a director at Legend Biotech Corp. On September 24, 2026, Mao Li acquired 20,986 ordinary shares with a transaction price of $0.00. This acquisition resulted in a post-transaction shareholding of 65,316 ordinary shares. The shares acquired are described as restricted share units (RSUs), with specific vesting schedules detailed in the filing. Each RSU represents a contingent right to one ordinary share, and the vesting is subject to continued service with the company.